Home / Themes / GLP-1 Long '24: Improved Looks
GLP-1 Long '24: Improved Looks
Last updated
Theme thesis · 3/5 sections · Tickers 5 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe current thesis for the subtheme **GLP-1 '24: Improved Looks** is bullish, focusing on the potential growth in consumer spending on products and services tha
Thesis
The current thesis for the subtheme GLP-1 '24: Improved Looks is bullish, focusing on the potential growth in consumer spending on products and services that enhance appearance and dating prospects. With the increasing prevalence of GLP-1 drugs, more individuals are experiencing significant weight loss, thus boosting demand in sectors like cosmetic surgery, online dating, and fashion. This trend is expected to continue as these drugs become more accessible, influencing consumer behavior towards improved self-image and social engagement.
Bull case
Increased usage of GLP-1 drugs has led to significant weight loss, driving demand for cosmetic surgeries and related products, benefiting companies like ESTA and AIRS.
Online dating platforms, such as MTCH, are experiencing higher user engagement as people feel more confident about their improved appearances.
Fashion retailers catering to changing body sizes, like CURV, are seeing increased sales as consumers update their wardrobes post-weight loss.
Bear case
The high cost of GLP-1 drugs may limit widespread adoption, potentially dampening the expected surge in demand for appearance-related products.
Economic downturns or rising interest rates could reduce discretionary spending, negatively impacting consumer sectors like fashion and online dating.
Potential side effects or health risks associated with long-term GLP-1 usage could lead to a decline in drug popularity and subsequent impact on related industries.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Consumer Spending on Fashion | Monthly | Tracks changes in fashion retail sales | Google_Sheets |
| User Engagement on Dating Platforms | Monthly | Measures activity and engagement on dating sites | Google_Sheets |
| GLP-1 Prescription Rates | Monthly | Indicates the adoption rate of GLP-1 drugs | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| BMBL_b9779f08 | mid-2026 | 2026-05-01 | 2026-06-30 | Launch of the new AI-first cloud-native platform for Bumble Date (Bumble Date 2.0 infrastructure). | This platform is expected to revolutionize Bumble's innovation speed and flexibility, enabling personalized experiences, enhanced safety, and continuous improvements, which management believes will unlock long-term product-led growth. | Ticker | 2025-11-05 | earnings_transcript | BMBL (ticker) |
| BMBL_c0f0c9d9 | next year | 2026-01-01 | 2026-12-31 | Introduction of a new, stand-alone AI product within Bumble's portfolio. | This product is envisioned to be unique in the market, leveraging AI for 'precise search' in dating, potentially expanding Bumble's offerings beyond traditional discovery and opening new avenues for growth and monetization. | Ticker | 2025-11-05 | earnings_transcript | BMBL (ticker) |
| BMBL_6615c0a3 | In 2026 | 2026-01-01 | 2026-12-31 | Addition of group and community discovery features to the Bumble BFF app. | This expansion aims to enhance the BFF experience, allowing users to more easily find friends and form communities offline, strengthening Bumble's position as a platform for connection and potentially driving growth in new social experiences. | Ticker | 2025-11-05 | earnings_transcript | BMBL (ticker) |
| BMBL_d293a5ef | in just a few months | 2026-04-01 | 2026-06-30 | Relaunch of the entire Bumble experience, including the new cloud-native technology stack (Tech Stack 2.0) and a rearchitected user experience (Bumble 2.0). | This is the core of Bumble's transformation, expected to drive user re-engagement, accelerate user growth, and enable more effective monetization through faster innovation and deeper personalization. Success is bullish, delays or poor reception are bearish. | Ticker | 2026-03-11 | earnings_transcript | BMBL (ticker) |
| BMBL_fc5f57df | will be launched in beta soon. | 2026-04-01 | 2026-06-30 | Beta launch of "b", Bumble's integrated AI personal dating assistant and matchmaker. | This feature aims to improve match quality, relevance, and user satisfaction by learning individual preferences, potentially boosting engagement, retention, and monetization. Successful beta is bullish, poor performance is bearish. | Ticker | 2026-03-11 | earnings_transcript | BMBL (ticker) |
| BMBL_50fb7f11 | As we move through 2026, we expect our revenue headwinds to moderate as the impacts of recent trends in our operating metrics flow through the financials. | 2026-04-01 | 2026-12-31 | Moderation of year-over-year revenue declines and sequential stabilization/improvement in key operating metrics like active users and payers. | This is a critical indicator of the success of Bumble's quality reset and product innovation strategy, signaling a potential return to growth and a positive shift in investor sentiment. Achievement is bullish, continued declines are bearish. | Ticker | 2026-03-11 | earnings_transcript | BMBL (ticker) |
| BMBL_90a26eaf | benefits to increase through 2026 | 2026-03-13 | 2026-12-31 | Continued increase in adoption and financial benefits from direct payment alternatives to in-app purchases in the U.S. | This strategy directly improves gross margins and long-term profitability by reducing platform fees. Greater adoption and sustained benefits are bullish for financial performance. | Ticker | 2026-03-11 | earnings_transcript | BMBL (ticker) |
| BMBL_d9a3779f | currently in discussions to refinance our existing debt obligations due January 2027 | 2026-03-13 | 2027-01-31 | Successful refinancing of $588 million in debt obligations maturing in January 2027. | Favorable refinancing terms would strengthen the balance sheet and provide financial flexibility for strategic investments. Unfavorable terms or delays could negatively impact liquidity and investor confidence. | Ticker | 2026-03-11 | earnings_transcript | BMBL (ticker) |
| ABBV_ac706a0a | US submission is planned for the second quarter | 2026-04-01 | 2026-06-30 | US regulatory submission for RINVOQ in alopecia areata. | This is a critical step towards potential US market entry for RINVOQ in alopecia areata, a significant dermatological condition. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_171a2b75 | Over the course of 2026 | 2026-04-26 | 2026-12-31 | Readout of Phase 3 data for both RINVOQ and lutekizumab in hidradenitis suppurativa. | Positive data could lead to new indications for RINVOQ and establish lutekizumab as a lead asset, significantly expanding AbbVie's immunology franchise. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_1bed7b86 | This year | 2026-04-26 | 2026-12-31 | Data from the Crohn's disease platform study evaluating SKYRIZI in combination with ABBV 3A2 and lutekizumab. | This data could demonstrate superior efficacy for patients, strengthening SKYRIZI's position and AbbVie's overall IBD portfolio, especially for patients who have already received SKYRIZI. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_dfdda14f | anticipate seeing efficacy results later this year | 2026-04-26 | 2026-12-31 | Efficacy results from dose escalation studies for ABBV 619, an in vivo CD19 CAR T platform for autoimmune diseases. | Positive results could signal a transformative new approach to autoimmune diseases, offering deep and durable remission and a significant long-term growth driver. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_5d3fb65c | initiating a phase three study this year | 2026-04-26 | 2026-12-31 | Initiation of a Phase 3 study for tmAbA in an all-comers population in combination with bevacizumab for colorectal cancer. | This advances tmAbA into late-stage development for a multibillion-dollar opportunity in CRC, bolstering AbbVie's oncology pipeline. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_327b8be4 | data is expected around the middle of this year. | 2026-05-01 | 2026-06-30 | Phase 2 study data readout for ABBV 932 in bipolar depression. | Positive data could position ABBV 932 as a next-generation asset in psychiatry, potentially contributing to the replacement of Vraylar at its LOE in 2030. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_cba492a1 | an approval decision is expected this year. | 2026-04-26 | 2026-12-31 | US regulatory approval decision for Trenebody, a rapid-onset short-acting toxin for aesthetics. | Approval and subsequent launch could stimulate the aesthetics market by attracting new patients and ultimately accrue to Botox share, increasing overall revenue. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_80210779 | we will shortly see a readout over a head-to-head study with Entyvio. | 2026-04-26 | 2026-06-30 | Readout of head-to-head study data for SKYRIZI versus Entyvio in ulcerative colitis. | Positive data could provide a significant opportunity to continue SKYRIZI's momentum and leadership in the IBD market, differentiating it from other competitors. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| CURV_8b384cd0 | by the first half of the year | 2026-03-19 | 2026-06-30 | Finalization of Torrid's store optimization plan, completing the closure of up to an additional 30 unproductive stores. | This action will fully rationalize the store footprint, leading to an expected $40 million in additional expense savings for fiscal 2026 and supporting EBITDA margin expansion. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_290cb242 | for 2026 | 2026-01-01 | 2026-12-31 | Execution of targeted marketing strategies to accelerate customer file growth, focusing on reactivating 7 million lapsed customers, improving segmentation, personalization, and refining the loyalty program. | This is the company's top priority, aiming to drive new customer acquisition, reactivate lapsed customers, and increase purchase frequency, which is crucial for sales growth and long-term customer lifetime value. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_16278e9e | in 2026 | 2026-01-01 | 2026-12-31 | Achieving projected 60% growth in sub-brand sales to approximately $110 million in 2026 and testing new scaling approaches like pop-up experiences and expanded in-store assortments. | Sub-brands are margin-accretive and serve as customer acquisition engines, attracting new shoppers and driving higher spend, which could positively impact overall sales and profitability. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_94d63ed7 | positive impact in the second half of the year | 2026-06-01 | 2026-12-31 | Full reintroduction and scaling of the footwear business, including the launch of the boot business in Q3, shifting from a first-half headwind to a second-half positive impact. | This is expected to recapture lost direct revenue and attachment-driven sales, driving stronger attachment rates, improved profitability, and a positive comparable sales impact in the second half of 2026. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_734fc95d | in 2026 | 2026-01-01 | 2026-12-31 | Expansion of the opening price point (OPP) strategy to represent closer to 40% of the total assortment. | This strategy is driving conversion and units per transaction, serving as a critical component for customer file growth (reactivation, acquisition, frequency), and is expected to be highly accretive due to cost-engineering and sourcing strength. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_576e78ea | For the full year | 2026-01-01 | 2026-12-31 | Achievement of adjusted EBITDA margin expansion of up to 140-150 basis points in fiscal 2026. | This indicates improved profitability driven by SG&A leverage from the rationalized store footprint and optimized cost structure, which is a key financial goal for the company and could positively impact valuation and investor sentiment. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_28d68144 | for the full year | 2026-01-01 | 2026-12-31 | Torrid aims to grow sub-brand sales by approximately 60% for the full year, reaching roughly $110 million and expanding to 12% of total net sales. | Sub-brands are margin-accretive and act as customer acquisition engines. Achieving this growth would positively impact net sales and profitability, while falling short would be bearish. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| CURV_b24ee74c | in 2026 | 2026-01-01 | 2026-12-31 | Successful execution of targeted marketing strategies to acquire new customers, reactivate lapsed ones, and deepen loyalty and purchase frequency of existing customers. | This is the company's primary focus for 2026, expected to drive future sales and long-term value creation. Growth in the customer file is bullish, while stagnation or decline would be bearish. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| CURV_50f2c4e6 | in the second quarter | 2026-04-01 | 2026-06-30 | Substantial completion of the store optimization program with the closure of an additional 7 to 8 structurally unproductive locations. | This program generates cost savings ($40 million expected in fiscal 2026) that are reinvested into growth initiatives and has rightsized the store fleet for better productivity, positively impacting profitability. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| CURV_f56e7b72 | additional recoveries expected as the claims process progresses | 2026-06-01 | 2026-12-31 | Recovery of additional tariff refunds from the first phase ($9-$11 million) and a forthcoming second phase ($1.5-$2.5 million). | These refunds are not included in current guidance and represent a potential upside of $10.5 million to $13.5 million, which would positively impact profitability. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| BMBL_46d0cf30 | a series of product updates planned as fast follows, including the introduction of functionality designed to bring members together in curated, real-world settings. | 2026-07-01 | 2026-12-31 | Introduction of new Bumble BFF functionalities, including group discovery and features to facilitate curated, real-world social settings, extending into group dating. | This initiative targets Gen Z's social preferences, aiming to deepen engagement within BFF and create new pathways into Bumble Date, potentially expanding the user base and increasing overall platform activity. Successful adoption is bullish. | Ticker | 2026-03-11 | earnings_transcript | BMBL (ticker) |
| ABBV_800b4101 | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | US commercial approval decision for tevapadon in Parkinson's disease. | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_47f622ef | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_ced91140 | by Q3 or so | 2026-07-01 | 2026-09-30 | Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| CURV_ae4fe6f9 | in the back half of the year | 2026-07-01 | 2026-12-31 | Launch of two new bras within the Curve intimate apparel brand. | Bras are a key product category that drives strong customer acquisition, reactivation, and long-term loyalty, potentially boosting sales and customer engagement in the intimate apparel segment. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_9cd7ebbc | in the back half of the year | 2026-07-01 | 2026-12-31 | Rollout and expansion of new fleece programs and knit dressing capsule collections. | These new product offerings are expected to be advantageous and contribute to sales growth, particularly in the back half of the year, by expanding the product assortment. | Ticker | 2026-03-19 | earnings_transcript | CURV (ticker) |
| CURV_36938b6a | second half of the year | 2026-07-01 | 2026-12-31 | The footwear program, which was a headwind in the first half due to restructuring, is expected to resolve and return to full strength. | This is anticipated to become a tailwind for comparable sales in the second half, providing a sizable benefit and historically enhancing attachment rates and overall customer spend. A successful return is bullish for sales and customer engagement, while delays or underperformance would be bearish. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| CURV_94f36efe | relaunching an expanded reconceived casting call in July | 2026-07-01 | 2026-11-30 | The relaunch of an expanded, year-round Casting Call platform, including a Times Square activation, mall events, and in-store parties, culminating in a winner announcement in November. | Casting Call is a key platform designed to drive customer acquisition, reactivation, and retention, and has historically increased brand awareness. Successful execution is bullish for customer file growth and brand engagement. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| CURV_f5e82e96 | for the second half | 2026-07-01 | 2026-12-31 | The actual tariff rate applied to goods in the second half of fiscal 2026. Guidance assumes a step-up to 15% from 10%. | If tariffs remain at 10% for the full year, it would offset potential freight-related headwinds, which would be bullish for margins. An escalation beyond 15% or worse-than-expected freight headwinds would be bearish. | Ticker | 2026-06-04 | earnings_transcript | CURV (ticker) |
| ABBV_c5da1469 | anticipated in the fourth quarter | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ in nonsegmental vitiligo. | Approval would expand RINVOQ's market to a new systemic indication, potentially adding to its multi-billion dollar sales trajectory. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |